The landscape of metabolic peptide research has evolved dramatically over the past few years. What began with single-receptor agonists has rapidly progressed into dual and triple-receptor targeted therapies. In 2026, researchers are primarily focused on three dominant molecules: Semaglutide, Tirzepatide, and the emerging Retatrutide. Understanding the distinct mechanisms, receptor affinities, and clinical trial outcomes of […]
